优化一种新的2+2BCMA × CD3双特异抗体,以最大限度地减少细胞因子释放和强效
Danqing Wu1, Lini Huang1, Gaowa Naren1
1EpimAb Biotherapeutics Co., Ltd., Shanghai, China.
Molecular cancer therapeutics
|June 4, 2025
概括
开发了一种针对B细胞成熟抗原和CD3的新型双特异性抗体,以减少细胞因子释放综合征. 这种抗体在临床前研究中显示出对多发性骨髓瘤的强大疗效,并改善了临床前研究中的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 细胞因子释放综合征 (CRS) 是双特异性T细胞参与者的临床应用的一个重要障碍.
- 对多发性骨髓瘤 (MM) 需要有效的治疗方法,特别是那些具有更好的安全性.
研究的目的:
- 开发一种针对B细胞成熟抗原 (BCMA) 和CD3的新型双特异性抗体,用于多发性骨髓瘤治疗.
- 为减少细胞因子释放而设计抗体,同时保持强大的抗瘤疗效.
- 评估结合臂几何,价值和抗CD3亲和力对安全性和疗效的影响.
主要方法:
- 使用Fabs-in-tandem (FIT) 几何学与cis配置构建双特异分子.
- 产生具有不同亲和力的抗CD3单克隆抗体 (mAbs).
- 在体外和体内对不同双特异格式的评估,包括具有不同值和CD3亲和度的FIT-Ig,与tandem scFv参考相比.
- 评估重定向T细胞细胞毒性,细胞因子释放和与目标无关的T细胞激活.
- 在人类外周血液单核细胞移植小鼠和Cynomolgus子中进行临床前验证.
主要成果:
- 结合臂的价值和CD3亲和力都被证明会影响重定向的T细胞细胞毒性.
- 具有2+2结合价值和中等CD3亲和度的FIT-Ig格式 (CD3med FIT-Ig) 实现了与参考合scFv.v.相当的强烈抗瘤活性.
- 与参考基因相比,CD3med FIT-Ig诱导的细胞因子释放量显著减少.
- 在FIT-Ig格式的双等效CD3结合并没有导致与目标无关的T细胞激活.
- 在动物模型中证实了CD3med FIT-Ig的良好的安全性和有效性.
结论:
- CD3med FIT-Ig (EMB-06) 是一种有希望的双特异性抗体,用于多发性骨髓瘤.
- 这种新型格式通过显著减少细胞因子释放,提供了差异化的安全概况.
- 设计的双特异性抗体保持强大的抗瘤疗效,解决T细胞吸引疗法的关键挑战.
相关概念视频
In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...


